Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Reliq Health Technologies

DB:MHN2
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MHN2
DB
CA$55M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Reliq Health Technologies Inc., a healthcare technology company, engages in the development of mobile software solutions for community care market. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
  • Reliq Health Technologies has significant price volatility in the past 3 months.
MHN2 Share Price and Events
7 Day Returns
9.9%
DB:MHN2
4.1%
DE Healthcare Services
7.3%
DE Market
1 Year Returns
35.3%
DB:MHN2
0.9%
DE Healthcare Services
-17.7%
DE Market
MHN2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Reliq Health Technologies (MHN2) 9.9% -29.5% -17.2% 35.3% 152.3% -
DE Healthcare Services 4.1% -8.3% -18.1% 0.9% 24.9% 85.3%
DE Market 7.3% -17.9% -25.8% -17.7% -25.6% -29%
1 Year Return vs Industry and Market
  • MHN2 outperformed the Healthcare Services industry which returned 0.9% over the past year.
  • MHN2 outperformed the Market in Germany which returned -17.7% over the past year.
Price Volatility
MHN2
Industry
5yr Volatility vs Market

MHN2 Value

 Is Reliq Health Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Reliq Health Technologies. This is due to cash flow or dividend data being unavailable. The share price is €0.2422.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Reliq Health Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Reliq Health Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:MHN2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in CAD CA$-0.11
TSXV:RHT Share Price ** TSXV (2020-03-30) in CAD CA$0.42
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 11.1x
Germany Market PE Ratio Median Figure of 400 Publicly-Listed Companies 16.36x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Reliq Health Technologies.

DB:MHN2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:RHT Share Price ÷ EPS (both in CAD)

= 0.42 ÷ -0.11

-3.91x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Reliq Health Technologies is loss making, we can't compare its value to the DE Healthcare Services industry average.
  • Reliq Health Technologies is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Reliq Health Technologies's expected growth come at a high price?
Raw Data
DB:MHN2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.91x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Healthcare Services Industry PEG Ratio Median Figure of 14 Publicly-Listed Healthcare Services Companies 2.29x
Germany Market PEG Ratio Median Figure of 254 Publicly-Listed Companies 1.2x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Reliq Health Technologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Reliq Health Technologies's assets?
Raw Data
DB:MHN2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in CAD CA$0.01
TSXV:RHT Share Price * TSXV (2020-03-30) in CAD CA$0.42
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.88x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.43x
DB:MHN2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:RHT Share Price ÷ Book Value per Share (both in CAD)

= 0.42 ÷ 0.01

29.03x

* Primary Listing of Reliq Health Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Reliq Health Technologies is overvalued based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess Reliq Health Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Reliq Health Technologies has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MHN2 Future Performance

 How is Reliq Health Technologies expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Reliq Health Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
28.6%
Expected Healthcare Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Reliq Health Technologies expected to grow at an attractive rate?
  • Unable to compare Reliq Health Technologies's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Reliq Health Technologies's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Reliq Health Technologies's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:MHN2 Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 28.6%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 8.5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.3%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:MHN2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:MHN2 Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:MHN2 Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-12-31 1 -8 -14
2019-09-30 0 -12 -12
2019-06-30 0 -12 -13
2019-03-31 0 -14 -16
2018-12-31 1 -13 -18
2018-09-30 2 -9 -16
2018-06-30 2 -8 -14
2018-03-31 2 -5 -7
2017-12-31 1 -4 -3
2017-09-30 0 -3 -3
2017-06-30 0 -2 -2
2017-03-31 0 -2 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Reliq Health Technologies is high growth as no earnings estimate data is available.
  • Unable to determine if Reliq Health Technologies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:MHN2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Reliq Health Technologies Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MHN2 Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:MHN2 Past Financials Data
Date (Data in CAD Millions) EPS *
2019-12-31 -0.11
2019-09-30 -0.10
2019-06-30 -0.11
2019-03-31 -0.14
2018-12-31 -0.16
2018-09-30 -0.15
2018-06-30 -0.14
2018-03-31 -0.07
2017-12-31 -0.05
2017-09-30 -0.04
2017-06-30 -0.04
2017-03-31 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Reliq Health Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of MHN2’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Reliq Health Technologies's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Reliq Health Technologies's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Reliq Health Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Reliq Health Technologies has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MHN2 Past Performance

  How has Reliq Health Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Reliq Health Technologies's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Reliq Health Technologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Reliq Health Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Reliq Health Technologies's 1-year growth to the DE Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
Reliq Health Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Reliq Health Technologies Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MHN2 Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.84 -13.73 9.71 3.80
2019-09-30 0.46 -12.37 8.27 3.87
2019-06-30 0.18 -13.00 7.63 5.15
2019-03-31 0.12 -16.35 11.74 4.06
2018-12-31 1.15 -17.74 14.12 3.50
2018-09-30 2.01 -16.00 13.64 3.08
2018-06-30 2.27 -13.80 13.36 1.42
2018-03-31 2.27 -6.66 7.24 1.31
2017-12-31 1.14 -3.33 3.46 1.25
2017-09-30 0.26 -2.93 2.67 0.77
2017-06-30 0.18 -2.46 2.05 0.72
2017-03-31 0.19 -2.95 1.59 0.60
2016-12-31 0.38 -2.81 1.66 0.44
2016-09-30 0.72 -2.76 2.01 0.47
2016-06-30 0.54 -2.84 2.02 0.45
2016-03-31 0.53 -2.85 2.90 0.27
2015-12-31 0.35 -4.96 2.86 0.32
2015-09-30 0.03 -4.75 2.22 0.31
2015-06-30 0.03 -4.56 2.12 0.27
2015-03-31 0.03 -3.53 1.07 0.21
2014-09-30 0.04 -1.19 0.56 0.40
2014-06-30 0.03 -1.11 0.43 0.43
2013-06-30 0.06 -0.89 0.44 0.51

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Reliq Health Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Reliq Health Technologies has efficiently used its assets last year compared to the DE Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Reliq Health Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Reliq Health Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Reliq Health Technologies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MHN2 Health

 How is Reliq Health Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Reliq Health Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Reliq Health Technologies's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Reliq Health Technologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Reliq Health Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Reliq Health Technologies has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Reliq Health Technologies Company Filings, last reported 2 months ago.

DB:MHN2 Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 1.96 0.00 0.39
2019-09-30 1.97 0.00 0.38
2019-06-30 2.66 0.00 0.47
2019-03-31 5.71 0.00 1.92
2018-12-31 7.24 0.00 3.39
2018-09-30 9.07 0.00 7.65
2018-06-30 11.83 0.00 9.92
2018-03-31 14.85 0.00 13.15
2017-12-31 4.09 0.00 3.33
2017-09-30 -0.33 0.00 0.10
2017-06-30 0.02 0.00 0.50
2017-03-31 -1.02 0.16 0.18
2016-12-31 -0.69 0.00 0.26
2016-09-30 -0.78 0.00 0.31
2016-06-30 -0.36 0.00 0.46
2016-03-31 1.61 0.00 0.60
2015-12-31 1.08 0.00 0.81
2015-09-30 0.96 0.00 1.28
2015-06-30 0.28 0.00 0.46
2015-03-31 1.61 0.00 1.61
2014-09-30 -0.53 0.27 0.06
2014-06-30 -0.48 0.00 0.01
2013-06-30 -0.01 0.05 0.08
  • Reliq Health Technologies has no debt.
  • Reliq Health Technologies has no debt compared to 5 years ago when it was 23.2%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Reliq Health Technologies has less than a year of cash runway based on current free cash flow.
  • Reliq Health Technologies has less than a year of cash runway if free cash flow continues to grow at historical rates of 45.2% each year.
X
Financial health checks
We assess Reliq Health Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Reliq Health Technologies has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MHN2 Dividends

 What is Reliq Health Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Reliq Health Technologies dividends.
If you bought €2,000 of Reliq Health Technologies shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Reliq Health Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Reliq Health Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:MHN2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 1.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 323 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 1%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:MHN2 Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Reliq Health Technologies has not reported any payouts.
  • Unable to verify if Reliq Health Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Reliq Health Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Reliq Health Technologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Reliq Health Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Reliq Health Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Reliq Health Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MHN2 Management

 What is the CEO of Reliq Health Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Lisa Crossley
COMPENSATION CA$226,600
TENURE AS CEO 4.2 years
CEO Bio

Dr. Lisa Crossley PhD, P.Eng. has been Chief Executive Officer of Reliq Health Technologies Inc. since January 18, 2016. Dr. Crossley was Chief Executive Officer of VitalHub Corp. Dr. Crossley served as Chief Executive Officer of Quantum Dental Technologies, Inc. Dr. Crossley served as the President and Chief Executive Officer of Natrix Separations, Inc., (Formerly, Nysa Membrane Technologies Inc.), a biotech company. Dr. Crossley is an accomplished healthcare technology executive with a proven track record of successfully building and leading global tech companies. She has diverse experience across multiple market segments, including healthcare information technology, therapeutics, medical devices, life science tools and diagnostics. Prior to McMaster, Dr. Crossley served in Product Development at Dyax Corporation in Cambridge, MA, where she directed the process development, technology transfer and large-scale contract manufacturing of Dyax’s lead therapeutic proteins. In this position, Dr. Crossley managed multi-disciplinary teams of scientists and engineers at contract analytical labs and manufacturing organizations in Europe, the U.S. and Canada. Dr. Crossley has consulted for several of North America’s largest Life Sciences Venture Capital companies, aiding in technical due diligence as well as designing comprehensive product development plans for early-stage portfolio companies. Since 2002, Dr. Crossley served as Scientific Advisor of The Sierra Legal Defense Fund in their successful appeal to the Supreme Court of Canada in the Harvard Oncomouse trial. Dr. Crossley has extensive experience in the field of biopharmaceutical manufacturing. Dr. Crossley serves on the Genome Alberta Board of Directors and on the Mitacs Research Council. She has acted as a Board Director for the Ontario Bioscience Innovation Organization (OBIO), Boyd Technologies and Women in Science and Technology Businesses (WSTB) and has held numerous Advisory Board appointments. Dr. Crossley has been Director of Moseda Technologies, Inc since January 18, 2016. Dr. Crossley has been recognized for her expertise in the field of protein and nucleic acid purification and asked to author a chapter on New Technologies in Biopharmaceutical Downstream Processing for a Blackwell Publishing text "by industry, for industry" entitled Advanced Technologies for Biopharmaceutical Processing. Dr. Crossley served as a Director of Viron Therapeutics, Inc. She was a member of the Council of Canadian Academies' Expert Panel commissioned by Industry Canada to conduct a comprehensive assessment of the State of Industrial R&D in Canada. Dr. Crossley served as Faculty of The Department of Chemical Engineering at McMaster University to dedicate herself full-time to Nysa since 2005. Dr. Crossley is a licensed Professional Engineer in the province of Ontario. Dr. Crossley holds a B.Sc. in Anatomy & Cell Biology from McGill University, as well as a B.Sc.E. and Ph.D. in Chemical Engineering from Queen’s University. Dr. Crossley received her post-doctoral training in the BioProcess Sector of The National Research Council of Canada’s Biotechnology Research Institute (NRC-BRI).

CEO Compensation
  • Lisa's compensation has increased whilst company is loss making.
  • Lisa's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Reliq Health Technologies management team in years:

2.5
Average Tenure
  • The tenure for the Reliq Health Technologies management team is about average.
Management Team

Lisa Crossley

TITLE
CEO & Director
COMPENSATION
CA$227K
TENURE
4.2 yrs

Matthew Lee

TITLE
Chief Financial Officer

Rob Prouse

TITLE
Chief Technology Officer
TENURE
1 yrs

Richard Sztramko

TITLE
Chief Medical Officer
TENURE
2.5 yrs

Bassma Ghali

TITLE
Chief Innovation Officer
Board of Directors Tenure

Average tenure of the Reliq Health Technologies board of directors in years:

1
Average Tenure
  • The average tenure for the Reliq Health Technologies board of directors is less than 3 years, this suggests a new board.
Board of Directors

Lisa Crossley

TITLE
CEO & Director
COMPENSATION
CA$227K
TENURE
4.2 yrs

Eugene Beukman

TITLE
Director
COMPENSATION
CA$64K
TENURE
4.7 yrs

Brian Storseth

TITLE
Independent Director
COMPENSATION
CA$120K
TENURE
3.7 yrs

Matthew Finnegan

TITLE
Medical Advisory Board Member
TENURE
1 yrs

Scott Howell

TITLE
Medical Advisory Board Member
TENURE
1 yrs

Larry Jones

TITLE
Medical Advisory Board Member
TENURE
1 yrs

Bruce Kinosian

TITLE
Medical Advisory Board Member
TENURE
1 yrs

Alexander Stojadinovic

TITLE
Medical Advisory Board Member
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • Reliq Health Technologies individual insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Mar 20 Sell Richard Sztramko Individual 13. Mar 20 13. Mar 20 -197,700 €0.18 €-36,032
31. Oct 19 Buy Richard Sztramko Individual 30. Oct 19 30. Oct 19 11,700 €0.40 €4,709
15. Jul 19 Buy Richard Sztramko Individual 15. Jul 19 15. Jul 19 136,000 €0.17 €23,617
13. Jun 19 Sell Brian Storseth Individual 06. May 19 07. Jun 19 -150,000 €0.14 €-19,088
X
Management checks
We assess Reliq Health Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Reliq Health Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MHN2 News

Simply Wall St News

MHN2 Company Info

Description

Reliq Health Technologies Inc., a healthcare technology company, engages in the development of mobile software solutions for community care market. It offers iUGO Health technology platform, a hardware and software solution that allows complex patients to receive care in the home. The company was formerly known as Moseda Technologies Inc. and changed its name to Reliq Health Technologies Inc. in May 2016. Reliq Health Technologies Inc. was incorporated in 2005 is headquartered in Hamilton, Canada.

Details
Name: Reliq Health Technologies Inc.
MHN2
Exchange: DB
Founded: 2005
CA$35,529,263
138,559,817
Website: http://www.reliqhealth.com
Address: Reliq Health Technologies Inc.
175 Longwood Road South,
Suite 406A,
Hamilton,
Ontario, L8P 0A1,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV RHT Common Shares TSX Venture Exchange CA CAD 22. Feb 2006
OTCPK RQHT.F Common Shares Pink Sheets LLC US USD 22. Feb 2006
DB MHN2 Common Shares Deutsche Boerse AG DE EUR 22. Feb 2006
Number of employees
Current staff
Staff numbers
0
Reliq Health Technologies employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/30 22:08
End of day share price update: 2020/03/30 00:00
Last estimates confirmation: 2018/10/29
Last earnings filing: 2020/03/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.